AstraZeneca Faslodex Is First Launch For Doubled Oncology Sales Force
AstraZeneca's Faslodex is the first launch to be detailed by the company's recently-expanded oncology sales force, following FDA approval of the estrogen receptor down-regulator April 25
You may also be interested in...
Using anonymous examples at the recent AACR meeting, FDA’s Tatiana Prowell highlights mistakes made and lessons learned in oncology drug reviews.
AstraZeneca expects to receive a pediatric exclusivity extension for the breast cancer agentNolvadex (tamoxifen) based on studies in McCune-Albright syndrome
AstraZeneca plans to hire more in-house sales reps and decrease its "substantial reliance on contract sales organizations," Senior VP-Commercialization and Portfolio Management David Brennan said at the company's half-year results presentation in London Aug. 1.